Challenges and Opportunities With Oncology Drug Development in China

被引：24

作者：

Bajaj, Gaurav ^{[1
]}

Gupta, Manish ^{[1
]}

Wang, Hwei-Gene Heidi ^{[2
]}

Barrett, Jeffrey S. ^{[3
]}

Tan, Matthew ^{[2
]}

Rupalla, Katrin ^{[2
]}

Bertz, Richard ^{[1
]}

Sheng, Jennifer ^{[1
]}

机构：

[1] Bristol Myers Squibb, Princeton, NJ 08648 USA

[2] Bristol Myers Squibb, Shanghai, Peoples R China

[3] Sanofi Pasteur, Swiftwater, PA USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷 / 02期

关键词：

CELL LUNG-CANCER; BIM DELETION POLYMORPHISM; CHRONIC MYELOID-LEUKEMIA; PHASE-I SAFETY; OPEN-LABEL; MONOCLONAL-ANTIBODIES; INTRINSIC RESISTANCE; METABOLIZING-ENZYMES; OBINUTUZUMAB GA101; IMATINIB-RESISTANT;

D O I：

10.1002/cpt.1017

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.

引用

页码：363 / 375

页数：13

共 87 条

[1] Purification and Characterization of Two New Allergens from the Venom of Vespa magnifica [J].

An, Su ;

Chen, Lingling ;

Wei, Ji-Fu ;

Yang, Xuening ;

Ma, Dongying ;

Xu, Xuemei ;

Xu, Xueqing ;

He, Shaoheng ;

Lu, Jia ;

Laiz, Ren .

PLOS ONE, 2012, 7 (02)

[2] A Guide to Rational Dosing of Monoclonal Antibodies [J].

Bai, Shuang ;

Jorga, Karin ;

Xin, Yan ;

Jin, Denise ;

Zheng, Yanan ;

Damico-Beyer, Lisa A. ;

Gupta, Manish ;

Tang, Meina ;

Allison, David E. ;

Lu, Dan ;

Zhang, Yi ;

Joshi, Amita ;

Dresser, Mark J. .

CLINICAL PHARMACOKINETICS, 2012, 51 (02) :119-135

[3]

Bayer, 2017, BAYER REC APPR CHIN

[4]

Center for Drug Evaluation and Research, 2017, CLIN PHARM BIOPH REV

[5] Cancer Statistics in China, 2015 [J].

Chen, Wanqing ;

Zheng, Rongshou ;

Baade, Peter D. ;

Zhang, Siwei ;

Zeng, Hongmei ;

Bray, Freddie ;

Jemal, Ahmedin ;

Yu, Xue Qin ;

He, Jie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132

[6]

Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0084195, 10.1371/journal.pone.0091809]

[7] A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers [J].

Chen, Y. ;

Jiang, J. ;

Zhang, J. ;

Tortorici, M. A. ;

Pithavala, Y. K. ;

Lu, L. ;

Ni, G. ;

Hu, P. .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (11) :679-687

[8] Axitinib plasma pharmacokinetics and ethnic differences [J].

Chen, Ying ;

Suzuki, Akiyuki ;

Tortorici, Michael A. ;

Garrett, May ;

LaBadie, Robert R. ;

Umeyama, Yoshiko ;

Pithavala, Yazdi K. .

INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) :521-532

[9] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[10]

China Food and Drug Administration (CFDA), 2017, PROV DRUG REG

← 1 2 3 4 5 6 7 8 9 →